Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

2.5K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

509
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
509
Regression Toward the Mean01:52

Regression Toward the Mean

7.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
7.3K
Odds Ratio01:09

Odds Ratio

2.2K
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
2.2K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

696
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
696

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

The Lancet. Neurology·2026
Same author

Task-oriented virtual reality and brain functional plasticity in progressive multiple sclerosis: A randomized controlled trial on upper limb rehabilitation.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Web-based family-reported outcomes to assess family functioning in multiple sclerosis: an Italian multicenter digital survey.

International journal of medical informatics·2026
Same author

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Lancet (London, England)·2026
Same author

Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity.

JAMA network open·2026

Related Experiment Video

Updated: Mar 20, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K

Estimating a treatment effect: Choosing between relative and absolute measures.

Maria Pia Sormani1, Paolo Bruzzi2

  • 1Biostatistics Unit, Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|May 22, 2016
PubMed
Summary

Understanding treatment effects in clinical trials is crucial. This report clarifies relative and absolute measures, aiding clinicians in comparing therapies, especially in multiple sclerosis (MS).

Keywords:
Treatment effectabsolute measuresrelative measures

More Related Videos

Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.1K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K

Related Experiment Videos

Last Updated: Mar 20, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.1K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Pharmacoeconomics

Background:

  • Treatment effect sizes in clinical trials can be relative (e.g., relative risk, odds ratio, hazard ratio) or absolute (e.g., absolute difference, number needed to treat).
  • Indirect treatment comparisons are increasingly common in diseases like multiple sclerosis (MS) due to multiple drugs being evaluated in independent trials.
  • Clinicians frequently question which measure (relative vs. absolute) is most appropriate for interpreting and comparing treatment effects.

Purpose of the Study:

  • To define and explain relative and absolute measures of treatment effect.
  • To provide numerical examples for calculating these measures.
  • To clarify the meaning and appropriate context for using each measure in clinical practice and research.

Main Methods:

  • Review and definition of common relative treatment effect measures (relative risks, odds ratios, hazard ratios).
  • Review and definition of common absolute treatment effect measures (absolute differences, numbers needed to treat).
  • Illustrative numerical examples demonstrating the calculation and interpretation of both relative and absolute measures.

Main Results:

  • Relative measures can yield different comparative figures than absolute measures when comparing treatments indirectly.
  • The choice between relative and absolute measures depends on the specific clinical question and context.
  • Understanding the distinct interpretations of each measure is vital for accurate treatment effect assessment.

Conclusions:

  • Both relative and absolute measures are valuable for quantifying treatment effects but offer different perspectives.
  • The report aims to equip clinicians with the knowledge to select and interpret the most relevant measure for indirect treatment comparisons.
  • Clear understanding of these measures enhances evidence-based decision-making in therapeutic areas like multiple sclerosis.